The Newborn Metabolic Screening Market To Take A Parabolic Turn With A CAGR Of 9.2%

Increasing birth rates across the world are expected to drive demand for newborn metabolic screening, as the risk of galactosemia, sickle cell disease, phenylketonuria, maple syrup urine disease, and cystic fibrosis is higher among infants. Various countries are implementing screening for metabolic diseases in newborns as a part of their immunization programs. To remain competitive and ensure a robust product pipeline, leading companies continue to identify potential assets through pilot screening programs, which typically have limited resources to see projects through the market.

According to a latest report published by Persistence Market Research, the global newborn metabolic screening market was valued around US$ 247 Mn in 2020, and is expected to witness an impressive CAGR of over 9% during the forecast period (2020 – 2030).

Get Sample Copy of Report @

Companies covered in Newborn Metabolic Screening Market Report


Bio-Rad Laboratories

Trivitron Healthcare Private Limited

BioMedomics, Inc.

Luminex Corporation


Synergy Medical Systems LLP

Agilent Technologies, Inc

Thermo Fisher Scientific, Inc

Zivak Technologies

Get To Know Methodology of Report @

 Key Takeaways from Market Study  

Sickle cell disease is expected to contribute more than 30% of revenue share to the market.

By sample, blood testing held the highest market share in 2019 due to efficient diagnostic results.

Europe holds a significant share of over 30% in the global newborn metabolic screening market.

Leading manufacturers are focused on strengthening their product portfolios and regional expansion through collaborations.

Hospitals are expected to hold significant market share, due to high number of screening programs being arranged in collaboration with hospitals.

The COVID-19 outbreak has had a negative impact on the market, as short-term lockdowns disturbed the production and supply chain of kits.

The market in the U.S is projected to expand at a CAGR of close to 10% through 2030.

The U.K market has a share of more than 17% in Europe, and is expected to progress at a CAGR of more than 12% over the next ten years.

“Increasing prevalence of new born metabolic diseases and rising adoption of related screening program will boost the global market,” says an analyst of Persistence Market Research.

Access Full Report...

Do you already have an account? Log in here

Posted in: USA/Canada

Join the discussion


To read and post comments you need to login or register